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Abstract: A Monte Carlo analysis was undertaken to measure the ability of a series of dynamic insulin 
sensitivity and secretion tests (DISST) to observe and quantify the time-varying effect of an insulin 
sensitizer drug. Physiological parameter values from an insulin resistant individual were used to simulate 
a series of DISST tests with the effects a hypothetical sensitizer drug (based on Metformin) that was 
assumed to elevate insulin sensitivity (D) by 50%, and have absorption (Dk1) and decay (Dk2) half-lives 
of ~30 and ~140 minutes respectively. Noise was added to data sampled from the simulation and allowed 
repeated identification of pharmaco-kinetic/dynamic parameters in clinically realistic data. The 
coefficients of variation (CV) of the drug variables in this Monte Carlo analysis were CV-D=0.9%, CV-
Dk1=116.3%, and CV-Dk2=41.4% respectively. Although the CV values for the drug kinetic rates did not 
indicate considerable stability, the identified time-varying insulin sensitivity profile was relatively 
accurate to the simulation profile (median error of 0.047 L/mU/min (~2%) and IQR of -0.093 to 0.184 
L/mU/min (-4% to 8%)). This result indicates that the proposed method for identifying drug parameters 
using a series of dynamic tests is able to capture the overall effect of the drug, but has a potentially 
limited ability to identify the drug parameters individually. Thus, the existing method of arduous, 
frequently-sampled steady-state tests for the measurement of drug pharmacokinetics and dynamics could 
be replaced with a series of sparsely-sampled dynamic tests. 
Keywords: Physiological modeling, pharmacokinetics/dynamics, parameter-identification, insulin 
sensitivity. 
 
1. INTRODUCTION 
Insulin sensitizer drugs are used in treating type 2 diabetes 
mellitus to minimise the incidence of hyperglycaemia in 
individuals who require aid to effectively regulate their blood 
glucose concentration. Although there is a reasonable 
quantity of studies investigating the long term effects of such 
drugs, there are a limited number of studies investigating the 
drugs’ single dose kinetics. Typically, the effect of these 
drugs are measured by the companies that produce them 
using arduous steady-state clamp tests that last the duration of 
the drug’s efficacy. These steady-state tests require five or 
ten minutely samples to enable feedback control for 
euglycemia. This approach is thus very costly, time 
consuming and intensive. 
This study investigates a series of sparsely sampled dynamic 
tests as a possible alternative for this clinically intense 
approach. Our group has previously presented the dynamic 
insulin sensitivity and secretion test (DISST) as a low-cost, 
comparatively low intensity, but relatively high resolution 
insulin sensitivity test that also measures the participants 
endogenous insulin production response (Lotz et al. 2010). It 
is hypothesised that a series of these dynamic tests may 
enable an observation of the change in effect of these drugs 
over time. To test this hypothesis, an in-silico Monte Carlo 
analysis is completed that simulates the expected level of 
clinical assay error and measures the ability of the novel 
identification methods to reproduce values of a theoretical 
sensitizer drug’s pharmaco-kinetics (PK) and pharmaco-
dynamics (PD).    
2. METHODS 
2.1 Virtual Participant 
The parameters used to construct the virtual participant of 
this study were obtained from a participant of the DISST 
pilot study (Lotz 2007, Lotz et al. 2010). This particular 
participant was very insulin resistant with suspected 
undiagnosed type 2 diabetes mellitus. The participant had a  
  
     
 
Table 1. Key parameters of the participant used to generate the virtual participant used in this study, where all terms are 
defined in Table 2 except for Ub, U1 and U2 which represent the basal, first and second phases of insulin production. 
significant insulin production rate, but a relative inability to 
effectively clear glucose. Thus, she could be the type of 
person who might gain an advantage from insulin sensitizer 
treatment, and is likely to represent the physiology of patients 
already on insulin sensitizer treatment. Some key anatomical 
and PK/PD parameters for this participant are summarised in 
Table 1. 
2.2 Model Equations 
This study will use a previously validated  physiological 
model (Lotz et al. 2010), defined: 
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where: equation nomenclature is defined in Table 2. 
For this analysis, saturation of hepatic insulin clearance is 
assumed to be negligible and thus, aI is set to zero and nL and 
nK are combined to a single parameter of insulin clearance 
from plasma (nT). 
If it is assumed that the drug is administered orally or 
subcutaneously, it would be reasonable to propose a very 
simple two-compartment model for the PKs of the theoretical 
insulin sensitizer drug. It is assumed for the purpose of this 
preliminary, proof-of-concept investigation, that the transport 
between compartments will be concentration-based and the 
drug will not re-enter the remote compartment from the 
active compartment. Figure 1 and Equations (6)-(8) define 
the model used in this study and the effect of the drug on 
insulin sensitivity: 
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where: Equation nomenclature is defined in Table 2  
Sym’ Definition units 
C Plasma C-peptide concentration mU/L 
Y Interstitial C-peptide conc. mU/L 
k1 Transport rate to interstitial 1/min 
k2 C-peptide transport rate to plasma  1/min 
nK Kidney clearance of plasma insulin 
and C-peptide 
1/min 
Un Endogenous insulin production rate 
profile 
mU/L/min 
I Plasma insulin concentration mU/L 
Q Interstitial insulin concentration mU/L 
nL Hepatic insulin clearance 1/min 
aI Saturation of hepatic clearance L/mU 
nI Transition of insulin between plasma 
and interstitial 
L/min 
xL First pass clearance of insulin 1 
Vp Plasma insulin distribution volume  L 
Vq Interstitial insulin distribution 
volume 
L 
G Glucose concentration mmol/L 
Gb Basal glucose concentration mmol/L 
Qb Basal interstitial insulin conc. mU/L 
pG Glucose dependant glucose 
clearance 
1/min 
SI Insulin sensitivity L/mU/min 
PX Exogenous glucose bolus mmol 
VG Glucose distribution volume L 
S Latent drug effect in remote 
compartment 
1 
P Drug effect in active compartment 1 
D Total potential proportional effect of 
drug bolus on SI  
1 
Dk1 Passive transport rate from remote to 
active compartments. 
1/min 
Dk2 Passive clearance from active 
compartment. 
1/min 
SI0 Basal insulin sensitivity  L/mU/min 
SI(t) Time variant insulin sensitivity L/mU/min 
Table 2. Nomenclature from Equations (1)-(8). 
 
Figure 1. Two compartment representation of the PKs of a 
theoretical sensitizer drug. 
Sex Age BMI [kg.m-2] 
Un [mU.min-1] Insulin clearance VG 
[L] 
SI 
[L/mU/min] Ub U1 U2 nL [min-1] xL [1] 
F 57 33.9 115.5 233.6 150.7 0.064 0.822 13.35 2.236 
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2.3 Proposed Protocol 
The effect of a theoretical insulin sensitizer drug during a 
series of DISST tests will be simulated in a virtual participant 
over the 12 hours. The PKs of the theoretical drug used in 
this study are based on those of Metformin (Pentikäinen et al. 
1979). Seven DISST tests will begin at two hour intervals 
with blood samples taken at t=0, 10 25 and 40 minutes in 
each test. Thus, the total length of this virtual simulation is 
760 minutes (12 hours, 40 minutes), and the total number of 
samples is 28. Each of the seven DISST tests requires 10g 
glucose and 1U insulin (intravenous) bolus immediately after 
the t=0 and 10 minute samples respectively. The sensitizer 
drug is administered at t=150 minutes toward the end of the 
second test. Hence the first two tests serve as a baseline so 
each subject is their own control. All samples are assayed for 
insulin, C-peptide and glucose. 
2.4 Parameter Identification 
This analysis will define Un, nT, xL, SI0, VG, D, Dk1 and Dk2 as 
variables to be identified. All other model parameters are 
assumed to be known through a-priori means (Lotz 2007, 
Van Cauter et al. 1992).  
Un, nT, xL, SI0 and VG are identified using previously 
presented methods: Un is identified using a typical 
deconvolution approach (Van Cauter et al. 1992), nT, xL, SI0 
and VG are identified using the iterative integral method 
(Docherty et al. 2009, Hann et al. 2005), SI0 and VG are 
identified using only data from the first 150 minutes of the 
proposed protocol and are then held constant.  
To identify the PK/PD of the sensitizer drugs, a 
comprehensive model of the glucose PDs must be generated. 
Combining Equations (5) and (8) provides: 
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The variables in Equations (9) and (10) are not separable in 
terms of the glucose data and as such the iterative integral 
method is not possible. To enable variable identification, an 
approximation of the P(t) profile must first be de-convolved 
from Equation (9). Equation (9) can be rearranged for P(t): 
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With the exception of G(t) all parameters of Equation (9) are 
known or have been identified. G(t) must be approximated 
with the highest possible accuracy following the drug 
administration. Steps 1-4 outline this process: 
1. Simulate a preliminary G(t) for the full duration of 
all tests. Initially, this is done using the values for 
SI0 and VG identified with the iterative integral 
method and the baseline data from the first 150 
minutes of the test, and then using SI(t) and VG 
(G(t)prelim). 
2. Define a linear interpolation between the measured 
data points (G(t)interp) 
3. Define a linear interpolation between the values of 
G(t)prelim at the sample times (G(t)preint) 
4. The difference between G(t)interp and G(t)preint is 
attributable to the effect of the sensitizer and thus 
Equation (12) can be used as an approximation of 
G(t): 
G(t)=G(t)prelim+G(t)interp-G(t)preint.  (12) 
With an approximation of G(t), P(t)approx can be evaluated in 
Equation (11). This profile is then used with Equation (10) in 
a non-linear least square Levenberg-Marquardt parameter 
identification method to find the values of Dk1, Dk2 and D 
that minimise the function in Equation (13). 
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Once the PK/PD values of Equation (13) have converged 
sufficiently, P(t) is re-evaluated using Equation (10). Thus, 
G(t) can be re-simulated, and steps 1-4 and the Levenberg-
Marquardt parameter identification process can be iterated. In 
total, 5 iterations are used, by which time parameter 
convergence is on the order of 1%.  
2.5 Concept Evaluation 
A Monte Carlo analysis is used to assess the ability of the 
identification method and proposed protocol to detect and 
quantify the PKs of the theoretical sensitizer drug. C-peptide, 
insulin and glucose concentration profiles are simulated using 
Equations (1)-(4), and (9) with the protocol from Section 2.3.  
The participant parameter values used in the simulation are 
shown in Table 1. The theoretical drug kinetics are based on 
those of Metformin (Pentikäinen et al. 1979): Dk1 is defined 
as 0.005/min, representing an absorption half-life of ~140 
minutes. Similarly Dk2 is defined as 0.0015/min, representing 
a clearance half-life of ~460 minutes. Finally, D is defined as 
0.5, meaning a 50% increase in insulin sensitivity could be 
expected if the full amount of the drug dose was in the active 
compartment. The three C-peptide, insulin and glucose 
profiles are ‘sampled’ at the prescribed times and this 
represents a noiseless set of data measurements.  
The Monte-Carlo simulation identifies the eight variables 
mentioned at the start of Section 2.4 a total of 1000 times 
using the method described. Each iteration has normally-
distributed random noise added to the noiseless glucose, 
insulin and C-peptide data sets. The magnitude of the added 
noise is in accordance with realistic clinical assay error 
(glucose: CV=2%, insulin: CV=3%, and C-peptide: CV=4% 
to a maximum of three standard deviations).  
  
     
 
The median and variation of the identified variables of 
Equations (9)-(10) are presented. Furthermore, the median 
and inter-quartile range (IQR) of the SI(t) re-simulations will 
be compared to the noiseless simulation of Equation (8) to 
assess the ability of the method to track the PDs of the drug. 
3. RESULTS 
Table 3 summarises the variation in the identified variables 
that define the drug PK/PDs in Equations (9)-(10). 
 True 
Value 
Mean 
(CV) 
Median 
(IQR) 
SI 
[L/mU/min] 2.236 
2.252 
(7.9%) 
2.240 
(2.112-2.355) 
Vg  
[L] 13.35 
13.36 
(4.5%) 
13.31 
(12.95-13.74) 
D  
[1] 0.5 
0.498 
(0.9%) 
0.500 
(0.498-0.500) 
Dk1  
[1/min] 0.005 
0.0103 
(116.3%) 
0.0060 
(0.0048-0.0086) 
Dk2 
[1/min] 0.0015 
0.0013 
(41.4%) 
0.0013 
(0.0010-0.0017) 
Table 3. The effect of noise on variable identification. 
Figure 2 shows the range of time-varying sensitivity profiles 
identified by the method described in Section 2.4. It can be 
seen that the median profile is approximately equal to the true 
value for the duration of the test. The identification method 
generally seems to slightly overestimate the drug absorption 
rate (Dk1). However the 100th percentile simulation shows 
that at some outliers drastically overestimate the absorption 
rate. These values must contribute to the higher than expected 
mean and CV for Dk1. The median and IQR of Dk1 indicates 
that the values typically identified are within expected ranges.
Table 4 summaries the residuals of the time varying insulin 
sensitivity profiles shown in Figure 2.  
 
Median (IQR) [L/mU/min] 
Basal Period 0.004 (-0.122, 0.158) 
2.5-6 hours 0.091 (-0.037, 0.224) 
6-12 hours 0.048 (-0.079, 0.183) 
Overall 0.047 (-0.093, 0.1842) 
Table 4. Residuals of the SI(t) profiles. 
4. DISCUSSION 
The simulated PKs of the composite, hypothetical sensitizer 
drug were relatively observable in the resulting glucose data 
using the proposed protocol and identification methods. The 
variation in SI (7.9%) was slightly larger than previous a 
Monte Carlo study (Lotz et al. 2008). This outcome was an 
artefact of the reduced sampling rate compared to the test 
protocol used in that study.  Hence, the increased variation 
was expected and to an extent, validated the other outcomes 
of this analysis.  
The proportional drug effect (D) measurement was 
particularly stable to noise (0.9%). However, the drug 
absorption (Dk1) and decay rate (Dk2) variables were 
considerably more susceptible to noise (116.3% and 41.4%, 
respectively). This considerable variation in the drug rate 
parameters did not have a significant effect on the ability of 
the protocol and identification method to trace the kinetic and 
dynamic behaviours of the theoretical drug (Table 4). The 
variation in the basal insulin sensitivity was comparable to 
the variation in SI(t). This result implies that parameter trade 
off occurs. Hence, although the methods presented might not 
be ideal for the identification of the variables individually,  
Figure 2. A comparison between the identified insulin sensitivity profiles and the ‘true’ value of insulin sensitivity for this in-
silico analysis. 
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they may be appropriate for predicting the overall activity of 
the drug over time. This is the key outcome of such tests as 
the PKs can be directly measured with direct species assays if 
desired.  
In particular, the findings of this study imply that a clinical 
pilot investigation of sensitizer kinetics could be undertaken. 
The existing option for the identification of sensitizer drugs 
PD/PKs is a continuous steady state test such as the 
euglycemic clamp. This test raises the participant’s insulin 
concentration with a continuous insulin infusion, and 
euglycaemia is maintained with variable rate of glucose 
infusion. This variable rate is defined by using feedback 
control of frequently sampled glucose samples. A specific 
drug dose will be administered at approximately 2.5-3 hours 
when the glucose infusion is generally stable.  This approach 
allows a more accurate estimation of the time-varying 
increase of the insulin sensitivity profile. However, it comes 
at the cost of significantly increased clinical burden and cost. 
Table 5 summarizes and compares the attributes of the 
multiple DISST approach to the existing option for tracing 
the kinetics and dynamics of insulin sensitizer drugs. 
 DISST protocol EIC protocol 
Blood samples  28 72-144 
Sample cost ($NZ) ~800-1600 ~200 
Down-time 80 minutes 
every two hours None 
Validation Sparse Extensive 
Physiological 
relevance 
Within normal 
range 
Hyper-
physiological 
Risk of 
hypoglycemia Very minimal Very minimal 
Table 5. The costs and benefits of the two proposed methods 
for observing the kinetics and dynamics of insulin sensitizer 
drugs. 
The overall identification method used in this analysis was 
comprised of two separate types of identification method. 
Initially, the iterative integral method was used to identify the 
insulin kinetic variables, and then the SI and VG from the test 
period prior to drug administration.  Following this, non-
linear least squares was used to identify the PK’s of the 
sensitizer drug. The iterative integral method could not 
identify all five parameters of Equations (9)-(10) as they are 
not. Furthermore, when the five-variable case was 
considered, the non-linear lest squares method was either 
unstable, or unable to converge. As such, the iterative integral 
method was used to identify SI and VG during the pre-drug-
dose baseline period, and a change in insulin sensitivity 
profile is then generated by the drug that allowed a non-linear 
least-squares identification of the three drug PK and PD 
variables. This strategy enabled relatively fast, very stable 
parameter identification. The 1000 simulation Monte Carlo 
analysis required approximately 3 hours of simulation time 
and the 0th and 100th percentile shown in Figure 2 show that 
none of the randomly generated data sets prompted 
identification failure. 
The identification process and the identified values could be 
further stabilised if one or more of the parameters of 
Equation (9) could be fixed. For example, the rate of drug 
absorption (Dk1) may be known, but not the maximal effect 
(D) or decay rate (Dk2). In this case, the non-linear least 
square step would only have two variables and variable trade-
off would be limited. Similarly, the decay rate could be 
predetermined or bounded in separate prior tests. 
There were some limitations in this investigation. In 
particular, the model was contrived for a theoretical drug 
based on published data and contains simplified PK’s that 
may not fully represent the true PK/PD’s of actual sensitizer 
drugs. Such omitted effects may include: 
1. Irreversible transport between the remote and active 
compartments is not representative of the kinetics of 
drugs administered subcutaneously. Absorption of the 
drug if taken orally is irreversible, and the model 
assumption is valid in this case. 
2. The drug may be designed for become stored in fat 
cells for delayed dispersion. This may be modelled 
with an added passive third compartment of insulin 
kinetics. 
3. The drug may include combined physiological effects 
such as: 
a. Glucose production suppression. This is not 
modelled as a time-variant variable in s 
investigation 
b. A combined secretagogue effect. This will be 
observable with the C-peptide measurement 
during the trial. 
c. Delayed absorption of food. This will not affect 
dynamic fasting tests, but will be an important 
attribute of the drug that is not quantified. 
4. It is likely that the drug’s effect on insulin sensitivity 
may be saturable, i.e. doubling the bolus may only 
increase sensitivity by 50-70% (Laakso et al. 1990, 
Natali et al. 2000). 
5. The drug may require molecular changes that take 
time to occur. This is not modelled as such, but will 
be observable ‘lumped-in’ with the rate of 
absorption parameter. 
All of these factors can be incorporated into the model and 
so, do not invalidate the findings of this analysis. However, 
the model appears to be close to the limit of identification in 
the presence of noise, and thus any further addition would 
probably require known kinetic behaviours and rates. 
Furthermore, the proposed protocol could potentially be used 
as a replacement for the hyperglycaemic clamp for the 
identification of the effect of secretagogue drugs.  The typical 
approach of endogenous insulin production identification by 
a deconvolution of C-peptide data could be used. Parameters 
for first and second phase insulin production could be 
obtained from this de-convoluted profile and the variables of 
  
     
 
Equations (6)-(8) could be identified for the case of the 
secretagogue. 
5. CONCLUSIONS 
The proposed multiple DISST protocol offers a 
comparatively low-intensity option for the identification of 
the kinetics and dynamic of insulin sensitizer drugs. The 
time-varying insulin sensitivity profiles identified in this in-
silico analysis were quite accurate. However, the variables 
that defined the profiles showed that identification trade-off 
was occurring. Thus, although the proposed protocol will 
enable the identification of the effect of the drug overall, 
uncertainty exists in the identified drug absorption and decay 
rate values. 
The findings of this study indicate that a pilot trial of this 
protocol and the identification methods discussed would 
enable the observation and quantification of insulin sensitizer 
drugs. However, the next step for this type of test would be 
an in-silico analysis of a particular drug, instead of the 
theoretical one discussed here. 
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